CTMX
CYTOMX THERAPEUTICS INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
CYTOMX THERAPEUTICS INC (CTMX) is held as common stock by 5 tracked hedge-fund managers, with a combined reported value of ~$71.11M; the largest are Steven Cohen, Baker Bros. Advisors, Ken Griffin. 2 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 3 trimmed. 1 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Cooling
Common-stock holders52 also report options
Congress trades1
Price$2.75vs quarter-end-26.67%
Sectors0
This quarter's moves
Top holderNew1
Added0
Trimmed / sold3
Steven CohenCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $18.66M0.1% of portfolio4,975,8262026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Baker Bros. Advisors | $18.66M | 0.1% | Hold |
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $491.3K— of portfolio131,0002026 Q2
Value $332.3K— of portfolio88,6002026 Q2
Value $188.6K— of portfolio50,3002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $491.3K | — | — |
| Ken GriffinPUT | $332.3K | — | — |
| Paul Tudor JonesCALL | $188.6K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.